{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:54:47Z","timestamp":1794588887900,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Adeno-associated virus (AAV)-based gene therapy has emerged as a promising approach for treating a variety of genetic disorders by delivering therapeutic genes to target tissues. There have been numerous publications reporting nonclinical assessments of immune responses to various AAV-based gene therapy products (GTPs). However, the immune response data from approved GTPs in humans have not been systematically reviewed, and the utility of the data generated in these clinical studies has not been evaluated. This manuscript is intended as a comprehensive review of the nonclinical and clinical immunogenicity data, with focus on adaptive immunity, from nine AAV-based GTPs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) between 2017 and early 2026. It also offers science-based recommendations to inform the future development of GTPs. The accumulated experience from these approved GTPs support a tailored, risk-based approach to immunogenicity monitoring: pre-existing anti-vector antibodies show limited association to clinical response and cellular immune response measurement via ELISpot have practical limitations in clinical studies. These findings advocate for simplified analytical strategies \u2014 tailored to the drug development stage and informed by nonclinical data \u2014 that incorporate clinical safety markers such as liver function tests, cardiac damage markers, and transgene protein expression as indicators of clinically meaningful immune responses.<\/jats:p>","DOI":"10.1208\/s12248-026-01303-1","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:29:06Z","timestamp":1788974946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity in Approved Adeno-Associated Virus-Based Gene Therapies: A Framework for a Tailored Assessment Strategy"],"prefix":"10.1208","volume":"28","author":[{"given":"Ching-Ha","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura I","family":"Salazar-Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Gorovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6699-8473","authenticated-orcid":false,"given":"Michael A.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"6","key":"1303_CR1","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D\u2019Ambrosio ES, et al. Current clinical applications of AAV-mediated gene therapy. Mol Ther. 2025;33(6):2479\u2013516.","journal-title":"Mol Ther"},{"key":"1303_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22137207","author":"M Aoun","year":"2021","unstructured":"Aoun M, Passerini I, Chiurazzi P, Karali M, De Rienzo I, Sartor G, et al. Inherited retinal diseases due to RPE65 variants: from genetic diagnostic management to therapy. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22137207.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1303_CR3","doi-asserted-by":"publisher","first-page":"e210268","DOI":"10.1212\/WNL.0000000000210268","volume":"104","author":"HJ McMillan","year":"2025","unstructured":"McMillan HJ, Baranello G, Farrar MA, Zaidman CM, Moreno T, De Waele L, et al. Safety and efficacy of IV Onasemnogene Abeparvovec for pediatric patients with spinal muscular atrophy: the phase 3b SMART study. Neurology. 2025;104(2):e210268.","journal-title":"Neurology"},{"key":"1303_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","volume":"26","author":"TY Yang","year":"2022","unstructured":"Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471\u201394.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"1303_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1208\/s12248-021-00628-3","volume":"23","author":"B Gorovits","year":"2021","unstructured":"Gorovits B, Azadeh M, Buchlis G, Harrison T, Havert M, Jawa V, et al. Evaluation of the humoral response to adeno-associated virus-based gene therapy modalities using total antibody assays. AAPS J. 2021;23(6):108.","journal-title":"AAPS J"},{"key":"1303_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.675897","volume":"12","author":"BA Hamilton","year":"2021","unstructured":"Hamilton BA, Wright JF. Challenges posed by immune responses to AAV vectors: addressing root causes. Front Immunol. 2021;12:675897.","journal-title":"Front Immunol"},{"issue":"1","key":"1303_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","volume":"99","author":"PS Kishnani","year":"2010","unstructured":"Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26\u201333.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1303_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41436-020-01080-y","volume":"23","author":"C Li","year":"2021","unstructured":"Li C, Desai AK, Gupta P, Dempsey K, Bhambhani V, Hopkin RJ, et al. Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med. 2021;23(5):845\u201355.","journal-title":"Genet Med"},{"issue":"3","key":"1303_CR9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1303_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101217","volume":"32","author":"M Braun","year":"2024","unstructured":"Braun M, Lange C, Schatz P, Long B, Stanta J, Gorovits B, et al. Preexisting antibody assays for gene therapy: considerations on patient selection cutoffs and companion diagnostic requirements. Mol Ther Methods Clin Dev. 2024;32(1):101217.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1303_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857276","volume":"13","author":"DA Gross","year":"2022","unstructured":"Gross DA, Tedesco N, Leborgne C, Ronzitti G. Overcoming the challenges imposed by humoral immunity to AAV vectors to achieve safe and efficient gene transfer in seropositive patients. Front Immunol. 2022;13:857276.","journal-title":"Front Immunol"},{"issue":"3","key":"1303_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","volume":"25","author":"B Gorovits","year":"2023","unstructured":"Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M, et al. Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J. 2023;25(3):47.","journal-title":"AAPS J"},{"issue":"1","key":"1303_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1208\/s12248-025-01192-w","volume":"28","author":"B Gorovits","year":"2026","unstructured":"Gorovits B, Azadeh M, Fiscella M, Harrison T, Hofer M, Janetzki S, et al. Assessment of immune responses against AAV encoded transgene products. AAPS J. 2026;28(1):43.","journal-title":"AAPS J"},{"issue":"5","key":"1303_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/156652307782151425","volume":"7","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther. 2007;7(5):316\u201324.","journal-title":"Curr Gene Ther"},{"issue":"4","key":"1303_CR15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nm1549","volume":"13","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med. 2007;13(4):419\u201322.","journal-title":"Nat Med"},{"key":"1303_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.omtm.2021.05.012","volume":"22","author":"KS Patton","year":"2021","unstructured":"Patton KS, Harrison MT, Long BR, Lau K, Holcomb J, Owen R, et al. Monitoring cell-mediated immune responses in AAV gene therapy clinical trials using a validated IFN-gamma ELISpot method. Mol Ther Methods Clin Dev. 2021;22:183\u201395.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"7","key":"1303_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","volume":"32","author":"BR Long","year":"2024","unstructured":"Long BR, Robinson TM, Day JRS, Yu H, Lau K, Imtiaz U, et al. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A. Mol Ther. 2024;32(7):2052\u201363.","journal-title":"Mol Ther"},{"issue":"8","key":"1303_CR18","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"key":"1303_CR19","unstructured":"FDA. Human gene therapy for Hemophilia 2020. Available from: https:\/\/www.fda.gov\/media\/113799\/download."},{"key":"1303_CR20","unstructured":"FDA. ITVISMA\u00ae (onasemnogene abeparvovec-brve) suspension, for intrathecal injection 2025. Available from: https:\/\/www.fda.gov\/media\/189857\/download."},{"key":"1303_CR21","unstructured":"FDA. LUXTURNA (voretigene neparvovec-rzyl) prescribing information. 2017. Available from: https:\/\/www.fda.gov\/media\/109906\/download."},{"key":"1303_CR22","unstructured":"FDA. OTARMENI\u2122 (lunsotogene parvec-cwha) suspension, for intracochlear infusion 2026. Available from: https:\/\/www.fda.gov\/media\/192098\/download."},{"key":"1303_CR23","unstructured":"FDA. KEBILIDI (eladocagene exuparvovec-tneq) prescribing information 2024. Available from: https:\/\/www.fda.gov\/media\/183530\/download."},{"key":"1303_CR24","unstructured":"FDA. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion, Prescribing Information 2019. Available from: https:\/\/www.fda.gov\/media\/126109\/download."},{"key":"1303_CR25","unstructured":"FDA. HEMGENIX (etranacogene dezaparvovec-drlb) prescribing information 2022. Available from: https:\/\/www.fda.gov\/media\/163467\/download."},{"issue":"17","key":"1303_CR26","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","volume":"361","author":"P Simioni","year":"2009","unstructured":"Simioni P, Tormene D, Tognin G, Gavasso S, Bulato C, Iacobelli NP, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med. 2009;361(17):1671\u20135.","journal-title":"N Engl J Med"},{"key":"1303_CR27","unstructured":"FDA. ROCTAVIAN (valoctocogene roxaparvovec-rvox) prescribing information 2023. Available from: https:\/\/www.fda.gov\/media\/169937\/download."},{"key":"1303_CR28","unstructured":"FDA. BEQVEZ (fidanacogene elaparvovec-dzkt) prescribing information 2024. Available from: https:\/\/www.fda.gov\/media\/178140\/download."},{"key":"1303_CR29","unstructured":"FDA. ELEVIDYS (delandistrogene moxeparvovec-rokl) prescribing information 2025. Available from: https:\/\/www.fda.gov\/media\/184855\/download."},{"key":"1303_CR30","unstructured":"EMA. Refusal of the marketing authorisation for Elevidys (delandistrogene moxeparvovec) 2025. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-refusal-marketing-authorisation-elevidys-delandistrogene-moxeparvovec_en.pdf."},{"key":"1303_CR31","unstructured":"FDA. Guidane for industry: immunogenicity assessment for therapeutic protein products 2014. Available from: https:\/\/www.fda.gov\/media\/85017\/download."},{"issue":"11","key":"1303_CR32","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31(11):3123\u20136.","journal-title":"Mol Ther"},{"key":"1303_CR33","unstructured":"EMA. EMA medicines database. Available from: https:\/\/www.ema.europa.eu\/en\/medicines."},{"key":"1303_CR34","unstructured":"FDA. Drug database for approved cellular and gene therapy products. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"1303_CR35","unstructured":"FDA. HEMGENIX (etranacogene dezaparvovec-drlb) pharmacology-toxicology review 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"1303_CR36","unstructured":"FDA. LUXTURNA (voretigene neparvovec-rzyl) Pharmacology-Toxicology Review 2017. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna."},{"key":"1303_CR37","unstructured":"EMA. UPSTAZA (eladocagene exuparvovec) human medicines european public assessment report 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/upstaza."},{"key":"1303_CR38","unstructured":"EMA. ROCTAVIAN (valoctocogene roxaparvovec-rvox) human medicines european public assessment report 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/roctavian."},{"issue":"4","key":"1303_CR39","doi-asserted-by":"publisher","first-page":"101577","DOI":"10.1016\/j.omtm.2025.101577","volume":"33","author":"Y Chung","year":"2025","unstructured":"Chung Y, Koehler SD, Cancelarich S, Gibson TM, Pregernig G, Becker L, et al. Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Mol Ther Methods Clin Dev. 2025;33(4):101577.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1303_CR40","unstructured":"FDA. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion, pharmacology-toxicology review 2019. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"1303_CR41","unstructured":"EMA. BEQVEZ (fidanacogene elaparvovec-dzkt) Human medicines european public assessment report 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beqvez."},{"key":"1303_CR42","unstructured":"FDA. BEQVEZ (fidanacogene elaparvovec-dzkt) pharmacology-toxicology review 2024. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/beqvez."},{"key":"1303_CR43","unstructured":"FDA. ELEVIDYS (delandistrogene moxeparvovec-rokl) pharmacology-toxicology review 2023. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"1303_CR44","unstructured":"EMA. HEMGENIX (etranacogene dezaparvovec-drlb) human medicines European public assessment report 2022. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hemgenix."},{"key":"1303_CR45","unstructured":"EMA. Guideline on immunogenicity assessment of therapeutic proteins 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf."},{"issue":"6","key":"1303_CR46","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/cpt.3568","volume":"117","author":"C Grimaldi","year":"2025","unstructured":"Grimaldi C, Richards S, Baltrukonis D, Sims Belouski S, Coble K, Dholakiya SL, et al. IQ survey results on current industry practices-part 1: immunogenicity risk assessment. Clin Pharmacol Ther. 2025;117(6):1596\u2013604.","journal-title":"Clin Pharmacol Ther"},{"key":"1303_CR47","doi-asserted-by":"publisher","first-page":"1581153","DOI":"10.3389\/fimmu.2025.1581153","volume":"16","author":"J Grudzinska-Goebel","year":"2025","unstructured":"Grudzinska-Goebel J, Benstein K, Bloem K, Cowan KJ, Gorovits B, Jadhav M, et al. Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform. Front Immunol. 2025;16:1581153.","journal-title":"Front Immunol"},{"issue":"2","key":"1303_CR48","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1208\/s12248-016-0030-z","volume":"19","author":"LI Salazar-Fontana","year":"2017","unstructured":"Salazar-Fontana LI, Desai DD, Khan TA, Pillutla RC, Prior S, Ramakrishnan R, et al. Approaches to Mitigate the Unwanted Immunogenicity of Therapeutic Proteins during Drug Development. AAPS J. 2017;19(2):377\u201385.","journal-title":"AAPS J"},{"issue":"1","key":"1303_CR49","doi-asserted-by":"publisher","first-page":"2324801","DOI":"10.1080\/19420862.2024.2324801","volume":"16","author":"S Tourdot","year":"2024","unstructured":"Tourdot S, Baltrunkonis D, Denies S, Devanarayan V, Grudzinska-Goebel J, Kromminga A, et al. Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. MAbs. 2024;16(1):2324801.","journal-title":"MAbs"},{"key":"1303_CR50","unstructured":"EU. Regulation on In vitro diagnostic medical devices. 2017."},{"issue":"3","key":"1303_CR51","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz M, Levy DI, Petropoulos CJ, Bashirians G, Winburn I, Mahn M, et al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol Ther. 2023;31(3):616\u201330.","journal-title":"Mol Ther"},{"issue":"22","key":"1303_CR52","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1080\/17576180.2025.2586976","volume":"17","author":"O Tounekti","year":"2025","unstructured":"Tounekti O, Shubow S, Wassmer S, Van Tuyl A, Yang L, Gong B, et al. 2025 white paper on recent issues in bioanalysis: redosing patients with AAV gene therapy; CRS immunogenicity risk; Shedding assays; NHP studies immunogenicity; CMC vs Bioanalytical assays; Artificial intelligence-powered genomic pipelines for NGS (PART 3A - recommendations on gene, cell, and vaccine therapies immunogenicity & technologies; Biotherapeutics & biosimilars immunogenicity assessment & clinical relevance PART 3B - Regulatory agencies\u2019 input on immunogenicity\/Technologies of biotherapeutics, gene, cell & vaccine therapies). Bioanalysis. 2025;17(22):1365\u2013409.","journal-title":"Bioanalysis"},{"key":"1303_CR53","unstructured":"FDA. LUXTURNA (voretigene neparvovec-rzyl) clinical review 2017. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna."},{"key":"1303_CR54","unstructured":"FDA. Immunogenicity testing of therapeutic protein products \u2014Developing and validating assays for anti-drug antibody detection 2019. Available from: https:\/\/www.fda.gov\/media\/119788\/download."},{"key":"1303_CR55","unstructured":"FDA. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion, clinical review memorandum 2019. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"1303_CR56","unstructured":"FDA. ELEVIDYS (delandistrogene moxeparvovec-rokl) clinical review 2023. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"key":"1303_CR57","unstructured":"FDA. HEMGENIX (etranacogene dezaparvovec-drlb) clinical pharmacology BLA review 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"1303_CR58","unstructured":"FDA. ROCTAVIAN (valoctocogene roxaparvovec-rvox) clinical pharmacology BLA review 2023. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/roctavian."},{"key":"1303_CR59","unstructured":"FDA. KEBILIDI (eladocagene exuparvovec-tneq) BLA clinical and clinical pharmacology review memorandum 2024. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/kebilidi."},{"key":"1303_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-3690-9_1","volume":"2768","author":"S Janetzki","year":"2024","unstructured":"Janetzki S. Important considerations for ELISpot validation. Methods Mol Biol. 2024;2768:1\u201313.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"1303_CR61","doi-asserted-by":"publisher","first-page":"415","DOI":"10.4155\/bio-2021-0007","volume":"13","author":"B Corsaro","year":"2021","unstructured":"Corsaro B, Yang TY, Murphy R, Sonderegger I, Exley A, Bertholet S, et al. 2020 white paper on recent issues in bioanalysis: vaccine assay validation, qPCR assay validation, QC for CAR-T flow cytometry, NAb assay harmonization and ELISpot validation (Part 3 - recommendations on immunogenicity assay strategies, NAb Assays, Biosimilars and FDA\/EMA immunogenicity guidance\/Guideline, gene & cell therapy and vaccine assays). Bioanalysis. 2021;13(6):415\u201363.","journal-title":"Bioanalysis"},{"key":"1303_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073196","author":"S Parajuli","year":"2026","unstructured":"Parajuli S, Gallagher T, Flotte TR. Immune toxicities in AAV gene therapy: overview for clinicians. Int J Mol Sci. 2026. https:\/\/doi.org\/10.3390\/ijms27073196.","journal-title":"Int J Mol Sci"},{"key":"1303_CR63","unstructured":"FDA. ZOLGENSMA (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion, BLA pharmacovigilance plan review memo 2019. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma."},{"key":"1303_CR64","unstructured":"FDA. ELEVIDYS (delandistrogene moxeparvovec-rokl) BLA pharmacovigilance plan review memo 2023. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/tissue-tissue-products\/elevidys."},{"issue":"1","key":"1303_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-024-84077-w","volume":"15","author":"RA Potter","year":"2025","unstructured":"Potter RA, Moeller IH, Khan S, Haegel H, Hollenstein A, Steiner G, et al. Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy. Sci Rep. 2025;15(1):4.","journal-title":"Sci Rep"},{"issue":"5","key":"1303_CR66","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41434-025-00531-y","volume":"32","author":"DC Gorecki","year":"2025","unstructured":"Gorecki DC, Kalinski P, Pomeroy J. Is dystrophin immunogenicity a barrier to advancing gene therapy for Duchenne muscular dystrophy? Gene Ther. 2025;32(5):561\u20138.","journal-title":"Gene Ther"},{"issue":"4","key":"1303_CR67","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","volume":"11","author":"M Coppens","year":"2024","unstructured":"Coppens M, Pipe SW, Miesbach W, Astermark J, Recht M, van der Valk P, et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. Lancet Haematol. 2024;11(4):e265\u201375.","journal-title":"Lancet Haematol"},{"issue":"11","key":"1303_CR68","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","volume":"124","author":"J Guy","year":"2017","unstructured":"Guy J, Feuer WJ, Davis JL, Porciatti V, Gonzalez PJ, Koilkonda RD, et al. Gene therapy for leber hereditary optic neuropathy: low- and medium-dose visual results. Ophthalmology. 2017;124(11):1621\u201334.","journal-title":"Ophthalmology"},{"key":"1303_CR69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400521","author":"V Valayannopoulos","year":"2025","unstructured":"Valayannopoulos V, Bance M, Carvalho DS, Greinwald JH Jr., Harvey SA, Ishiyama A, et al. DB-OTO gene therapy for inherited deafness. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2400521.","journal-title":"N Engl J Med"},{"key":"1303_CR70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173510","author":"SM Salabarria","year":"2024","unstructured":"Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D\u2019Souza P, et al. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest. 2024. https:\/\/doi.org\/10.1172\/JCI173510.","journal-title":"J Clin Invest"},{"key":"1303_CR71","unstructured":"FDA. HEMGENIX (etranacogene dezaparvovec-drlb) BLA approval letter November 22, 2022 2022. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix."},{"key":"1303_CR72","unstructured":"FDA. Gudiance for industry: long term follow-up after administration of human gene therapy products 2020. Available from: https:\/\/www.fda.gov\/media\/113768\/download."},{"issue":"9","key":"1303_CR73","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.ymthe.2020.06.001","volume":"28","author":"LA George","year":"2020","unstructured":"George LA, Ragni MV, Rasko JEJ, Raffini LJ, Samelson-Jones BJ, Ozelo M, et al. Long-term follow-up of the first in human intravascular delivery of AAV for gene transfer: AAV2-hFIX16 for severe Hemophilia B. Mol Ther. 2020;28(9):2073\u201382.","journal-title":"Mol Ther"},{"issue":"2","key":"1303_CR74","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ymthe.2020.12.008","volume":"29","author":"BR Long","year":"2021","unstructured":"Long BR, Veron P, Kuranda K, Hardet R, Mitchell N, Hayes GM, et al. Early phase clinical immunogenicity of Valoctocogene Roxaparvovec, an AAV5-mediated gene therapy for Hemophilia A. Mol Ther. 2021;29(2):597\u2013610.","journal-title":"Mol Ther"},{"issue":"24","key":"1303_CR75","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMc2212912","volume":"388","author":"CG Bonnemann","year":"2023","unstructured":"Bonnemann CG, Belluscio BA, Braun S, Morris C, Singh T, Muntoni F. Dystrophin immunity after gene therapy for Duchenne\u2019s muscular dystrophy. N Engl J Med. 2023;388(24):2294\u20136.","journal-title":"N Engl J Med"},{"issue":"14","key":"1303_CR76","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1056\/NEJMoa2510209","volume":"393","author":"JD Gillmore","year":"2025","unstructured":"Gillmore JD, Gane E, Taubel J, Pilebro B, Echaniz-Laguna A, Kao J, et al. Nexiguran Ziclumeran gene editing in hereditary ATTR with polyneuropathy. N Engl J Med. 2025;393(14):1375\u201386.","journal-title":"N Engl J Med"},{"issue":"120","key":"1303_CR77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002865","volume":"4","author":"J Bennett","year":"2012","unstructured":"Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4(120):120ra15.","journal-title":"Sci Transl Med"},{"key":"1303_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69917-9","author":"S Bing","year":"2026","unstructured":"Bing S, Eskandarian A, Smith S, Sajib AM, Warrington S, Saleh S, et al. Integrated computational and experimental immunoengineering of adeno-associated virus capsid T cell epitopes in mice. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-69917-9.","journal-title":"Nat Commun"},{"issue":"2","key":"1303_CR79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41551-023-01129-8","volume":"8","author":"SJ Bing","year":"2024","unstructured":"Bing SJ, Seirup M, Hoang TT, Najera SS, Britten C, Warrington SL, et al. Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus. Nat Biomed Eng. 2024;8(2):193\u2013200.","journal-title":"Nat Biomed Eng"},{"key":"1303_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.omtm.2022.01.005","volume":"24","author":"SJ Bing","year":"2022","unstructured":"Bing SJ, Justesen S, Wu WW, Sajib AM, Warrington S, Baer A, et al. Differential T cell immune responses to deamidated adeno-associated virus vector. Mol Ther Methods Clin Dev. 2022;24:255\u201367.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"1303_CR81","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1016\/j.ymthe.2018.09.013","volume":"26","author":"AR Giles","year":"2018","unstructured":"Giles AR, Sims JJ, Turner KB, Govindasamy L, Alvira MR, Lock M, et al. Deamidation of amino acids on the surface of adeno-associated virus capsids leads to charge heterogeneity and altered vector function. Mol Ther. 2018;26(12):2848\u201362.","journal-title":"Mol Ther"},{"issue":"12","key":"1303_CR82","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/j.xphs.2024.09.006","volume":"113","author":"N Jarvi","year":"2024","unstructured":"Jarvi N, Hofman K, Venkatesh A, Gorecki E, Balu-Iyer SV. Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses. J Pharm Sci. 2024;113(12):3457\u201369.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1303_CR83","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709\u201322.","journal-title":"Mol Ther"},{"key":"1303_CR84","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780","author":"M Muhuri","year":"2021","unstructured":"Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, et al. Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI143780.","journal-title":"J Clin Invest"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01303-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01303-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:02:47Z","timestamp":1790665367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01303-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":84,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["1303"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01303-1","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BG, CHL, CG, MAP and SI are employees of Regeneron Pharmaceuticals, Inc., and may hold stock and\/or stock options in the company. YX is an employee of Intellia Therapeutics.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are those of the authors and do not reflect the official policy of Regeneron Pharmaceuticals.","order":2,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"140"}}